Farlong Holding Corp. Targets $16M IPO, Nasdaq Listing Under 'AFA'
Ticker: AFA · Form: S-1/A · Filed: Oct 30, 2025 · CIK: 2054964
Sentiment: mixed
Topics: IPO, S-1/A, Dietary Supplements, Controlled Company, Emerging Growth Company, Nasdaq Listing, Herbal Products
Related Tickers: AFA
TL;DR
**Farlong's IPO is a high-risk bet on a 'controlled company' in the supplement space, with potential upside if their self-affirmed GRAS ingredients gain market traction, but significant governance concerns.**
AI Summary
Farlong Holding Corporation (AFA) is launching an initial public offering of 4,000,000 shares of common stock at an estimated price of $4.00 per share, aiming to raise $16,000,000 before underwriting discounts and expenses. The company, a science-driven healthcare and wellness firm, develops and distributes proprietary dietary supplements, including herbal products. Farlong has self-affirmed GRAS status for key botanical ingredients like Notoginseng saponin extract and Breviscapine flavonoid extract, though the FDA has not reviewed these conclusions. Post-IPO, KML Family Trust and KMA Trust will collectively hold 90.9% of voting power, making Farlong a 'controlled company.' The offering includes a 45-day over-allotment option for underwriters to purchase up to 15% additional shares, potentially increasing gross proceeds to $18,400,000. The company is an 'emerging growth company' and has applied to list its common stock on the Nasdaq Capital Market under the symbol 'AFA', with listing approval being a condition for the offering's closing.
Why It Matters
This IPO offers investors a chance to enter the growing health and wellness market through a company focused on traditional herbal knowledge combined with scientific validation, potentially disrupting the dietary supplement space. However, the 'controlled company' structure, with Karin Mei Huang holding 90.9% voting power, presents significant governance risks for new public shareholders. Competitively, Farlong's self-affirmed GRAS status for key ingredients could differentiate its products, but the lack of FDA confirmation means it operates in a less regulated segment than pharmaceutical companies, impacting market perception and trust. Employees and customers will see increased scrutiny and potential expansion as the company gains public capital.
Risk Assessment
Risk Level: high — The offering involves a high degree of risk, as explicitly stated on page 10 of the prospectus. Farlong will be a 'controlled company' with KML Family Trust and KMA Trust holding 90.9% of voting power post-IPO, concentrating control with Karin Mei Huang. Additionally, the company's products are dietary supplements, not FDA-approved drugs, and their self-affirmed GRAS conclusions have not been reviewed or confirmed by the FDA, introducing regulatory and market acceptance risks.
Analyst Insight
Investors should approach Farlong's IPO with extreme caution due to the 'controlled company' structure and the inherent risks of the dietary supplement market. A thorough due diligence on the company's financial performance, management team, and the scientific validation of its products is crucial before considering an investment. Monitor Nasdaq's listing approval and any changes in the company's 'controlled company' status.
Financial Highlights
- debt To Equity
- 0.0
- revenue
- $16,558,000
- operating Margin
- 10.0%
- total Assets
- $10,573,000
- total Debt
- $0
- net Income
- $1,013,000
- eps
- $0.03
- gross Margin
- 65.0%
- cash Position
- $1,557,000
- revenue Growth
- -1.2%
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Karin Mei Huang | Chief Executive Officer and Chairperson | $250,000 |
Key Numbers
- $4.00 — Estimated initial public offering price per share (Basis for IPO valuation)
- 4,000,000 — Shares of common stock offered (Total shares available in the IPO)
- 90.9% — Aggregate voting power held by Karin Mei Huang (Indicates 'controlled company' status post-IPO)
- 6.5% — Underwriting discounts per share (Cost of the offering)
- $16,000,000 — Gross proceeds to company without over-allotment (Capital raised from the IPO)
- $18,400,000 — Gross proceeds to company with full over-allotment (Maximum capital raised from the IPO)
- 15% — Over-allotment option for underwriters (Potential additional shares underwriters can purchase)
- $0.0001 — Par value per share of common stock (Nominal value of each share)
Key Players & Entities
- Farlong Holding Corporation (company) — Registrant for S-1/A filing
- Jackson Kwok (person) — Chief Executive Officer of Farlong Holding Corporation
- Karin Mei Huang (person) — Beneficial owner of KMA Trust and KML Family Trust, controlling 90.9% of voting power post-IPO
- KML Family Trust (company) — Shareholder holding 72.7% of common stock post-IPO
- KMA Trust (company) — Shareholder holding 18.2% of common stock post-IPO
- US Tiger Securities, Inc. (company) — Sole Book-Running Manager for the IPO
- U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
- Nasdaq Capital Market (regulator) — Intended listing exchange for Farlong's common stock
- Ying Li, Esq. (person) — Legal counsel from Hunter Taubman Fischer & Li LLC
- Fang Liu, Esq. (person) — Legal counsel from VCL Law LLP
FAQ
What is Farlong Holding Corporation's business model?
Farlong Holding Corporation is a science-driven healthcare and wellness company that develops product formulations and engages contract manufacturers to produce proprietary dietary supplements, including herbal products, which it then markets and distributes. The company focuses on combining traditional herbal knowledge with contemporary scientific techniques.
What is the estimated IPO price and number of shares for Farlong Holding Corporation?
Farlong Holding Corporation is offering 4,000,000 shares of common stock at an estimated initial public offering price of $4.00 per share. This offering aims to raise $16,000,000 before underwriting discounts and expenses.
Who will control Farlong Holding Corporation after the IPO?
After the IPO, Farlong Holding Corporation will be a 'controlled company' as KML Family Trust and KMA Trust will hold 72.7% and 18.2% of issued and outstanding shares, respectively. Karin Mei Huang, as the beneficial owner of these trusts, will exercise 90.9% of the aggregate voting power.
Has the FDA approved Farlong Holding Corporation's products?
No, Farlong Holding Corporation's products are dietary supplements and are not approved by the FDA. The company has self-affirmed GRAS conclusions for some botanical ingredients, but the FDA has not reviewed or confirmed these conclusions.
What are the key risks for investors in Farlong Holding Corporation's IPO?
Key risks include the 'controlled company' status, where Karin Mei Huang will hold 90.9% of voting power, and the fact that the company's dietary supplements are not FDA-approved, relying on self-affirmed GRAS status that the FDA has not confirmed. There is also no guarantee of Nasdaq listing approval.
What is an 'emerging growth company' and how does it apply to Farlong Holding Corporation?
An 'emerging growth company' (EGC) is defined under the JOBS Act of 2012. Farlong Holding Corporation has elected to comply with certain reduced public company reporting requirements available to EGCs for this prospectus and future filings, which can include less extensive disclosure obligations.
What is the purpose of the S-1/A filing by Farlong Holding Corporation?
The S-1/A filing is an amendment to Farlong Holding Corporation's S-1 registration statement, indicating updates or changes to the initial filing. It is part of the process to register securities for a public offering under the Securities Act of 1933.
What is the role of US Tiger Securities, Inc. in Farlong's IPO?
US Tiger Securities, Inc. is serving as the Sole Book-Running Manager for Farlong Holding Corporation's initial public offering. They are responsible for managing the offering and facilitating the sale of the common stock.
What are some of the specific ingredients Farlong Holding Corporation has self-affirmed as GRAS?
Farlong Holding Corporation has self-affirmed GRAS status for several ingredients, including Notoginseng (Panax notoginseng) saponin extract, Breviscapine (Erigeron breviscapus) flavonoid extract, Polygonum capitatum extract, Innerpure formulation, and Rodgersia sambucifolia Hemsl. Extract.
What is the significance of the Nasdaq listing for Farlong Holding Corporation?
Farlong Holding Corporation has applied to list its common stock on the Nasdaq Capital Market under the symbol 'AFA'. The closing of this offering is conditioned upon Nasdaq's final approval of the listing application, making it a critical step for the company to become publicly traded and access broader capital markets.
Risk Factors
- FDA Oversight and GRAS Status [high — regulatory]: Farlong's key botanical ingredients have self-affirmed GRAS status, but this has not been reviewed by the FDA. The company is subject to FDA regulations regarding dietary supplements, and any non-compliance could lead to enforcement actions, product recalls, or reputational damage.
- Dependence on Key Products [medium — financial]: The company's revenue is significantly dependent on a few proprietary dietary supplements. A decline in demand or increased competition for these core products could materially impact financial performance.
- Supply Chain and Manufacturing Risks [medium — operational]: Farlong relies on third-party manufacturers and suppliers for its products. Disruptions in the supply chain, quality control issues, or manufacturing defects could lead to production delays and impact product availability.
- Competition in the Health and Wellness Market [medium — market]: The dietary supplement market is highly competitive, with numerous established players and new entrants. Farlong faces competition from companies with greater brand recognition, larger marketing budgets, and more extensive distribution networks.
- Intellectual Property and Litigation [low — legal]: The company's success depends on its proprietary formulations and intellectual property. Infringement claims or challenges to its IP could result in costly litigation and hinder its ability to operate.
Industry Context
Farlong operates in the highly competitive health and wellness sector, specifically focusing on proprietary dietary supplements. The industry is characterized by increasing consumer interest in natural and herbal remedies, but also by stringent regulatory scrutiny and a crowded marketplace with established brands.
Regulatory Implications
The company's reliance on self-affirmed GRAS status for its ingredients presents a significant regulatory risk, as these have not been reviewed by the FDA. Farlong must comply with FDA regulations for dietary supplements, including labeling, manufacturing practices, and marketing claims.
What Investors Should Do
- Evaluate the regulatory risk associated with self-affirmed GRAS status.
- Assess the company's competitive positioning and reliance on a few key products.
- Monitor the impact of 'controlled company' status on corporate governance.
Glossary
- GRAS
- Generally Recognized As Safe. A designation by the FDA that a substance is generally recognized as safe for its intended use in food. (Farlong relies on self-affirmed GRAS status for its key botanical ingredients, which is not FDA-reviewed and carries regulatory risk.)
- Controlled Company
- A company where more than 50% of the voting power is held by an individual, a group of related individuals, or another company. (Post-IPO, Farlong will be a controlled company, with KML Family Trust and KMA Trust holding 90.9% of voting power, potentially limiting independent board oversight.)
- Emerging Growth Company
- A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. (Farlong qualifies as an EGC, allowing for reduced disclosure and reporting requirements under the JOBS Act.)
- Over-allotment Option
- An option granted to underwriters to purchase additional shares from the issuer at the IPO price, typically to cover excess demand. (Allows underwriters to purchase up to 15% more shares, potentially increasing the IPO's gross proceeds for Farlong.)
- Par Value
- The nominal or face value of a share of stock, as stated in the corporate charter. (Farlong's common stock has a par value of $0.0001, indicating a very low nominal value per share.)
Year-Over-Year Comparison
The S-1/A filing provides updated financial information for the fiscal year ended December 31, 2023. Revenue saw a slight decrease of 1.2% to $16,558,000 compared to the prior year. Net income increased by 10.5% to $1,013,000, resulting in improved EPS of $0.03. The company maintained a strong balance sheet with no debt and a cash position of $1,557,000. No new significant risk factors appear to have been added, but the existing ones remain relevant.
Filing Stats: 3,869 words · 15 min read · ~13 pages · Grade level 15.6 · Accepted 2025-10-30 06:25:42
Key Financial Figures
- $0.0001 — arlong Holding Corporation, p ar va lue $0.0001 per share. Prior to this offering, th
- $4.00 — public offering price per share will be $4.00 per share. We have reserved the symbol
- $1,196,000, b — underwriting discounts payable will be $1,196,000, based on an assumed public offering price
- $18,400,000 — writing discounts and expenses, will be $18,400,000. See “Expenses Relating to this
- $ — 1c;U.S. dollars,” “$,” and “dollars” ar
Filing Documents
- ea0230435-08.htm (S-1/A) — 6101KB
- ea023043508ex1-1_farlong.htm (EX-1.1) — 229KB
- ea023043508ex5-1_farlong.htm (EX-5.1) — 9KB
- ea023043508ex10-12_farlong.htm (EX-10.12) — 25KB
- ea023043508ex23-1_farlong.htm (EX-23.1) — 4KB
- ea023043508ex-fee_farlong.htm (EX-FILING FEES) — 13KB
- ex5-1_001.jpg (GRAPHIC) — 12KB
- tfarlong_logo.jpg (GRAPHIC) — 53KB
- tflowchart_001.jpg (GRAPHIC) — 255KB
- twwc_header.jpg (GRAPHIC) — 97KB
- twwc_sign.jpg (GRAPHIC) — 11KB
- twwc_footer.jpg (GRAPHIC) — 63KB
- ex23-1_001.jpg (GRAPHIC) — 8KB
- ex23-1_002.jpg (GRAPHIC) — 4KB
- 0001213900-25-103731.txt ( ) — 7191KB
- ea023043508ex-fee_farlong_htm.xml (XML) — 4KB
Risk Factors
Risk Factors   10 Disclosure Regarding Forward-Looking Statements   37
Use of Proceeds
Use of Proceeds   38 Dividend Policy   39 Capitalization   40
Dilution
Dilution   41 Management’s Discussion and Analysis of Financial Condition and Results of Operations   42
Business
Business   53 Management   78 Executive and Director Compensation   85 Certain Relationships and Related Party Transactions   88
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management   91
Description of Capital Stock
Description of Capital Stock   93 Shares Eligible for Future Sale   97
Underwriting
Underwriting   99 Legal Matters   103 Experts   103 Where You Can Find More Information   103 Index to Financial Statements   F-1 i Table of Contents About This Prospectus No dealer, salesperson, or other individual has been authorized to give any information or to make any representation other than those contained in this prospectus in connection with the offer made by this prospectus and, if given or made, such information or representations must not be relied upon as having been authorized by us. You should rely only on the information contained in this prospectus or in any related free writing prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation. For investors outside the United States:      We and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside the United States. Our logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames, and service marks that are the property of others. Solely for convenience, trademarks, tradenames, and service marks referred to in this prospectus may appear without the ® , ™, and SM symbols. References to our trademarks, tradenames, and s